Showing results (31-40 of 379) with videos related to
Sort By:
Pageof 38
Agents and Actions. Supplements|January 1, 1984
Remittive therapy in rheumatoid arthritis: clinical uses and mechanisms of actionP E LipskyThe American Journal of Medicine|October 31, 1983
Remission-inducing therapy in rheumatoid arthritisP E LipskyThe American Journal of Medicine|July 2, 1999
The clinical potential of cyclooxygenase-2-specific inhibitorsP E LipskyThe Journal of Rheumatology. Supplement|January 1, 1992
Immunopathogenesis and treatment of rheumatoid arthritisP E LipskyArthritis and Rheumatism|November 1, 1989
The control of antibody production by immunomodulatory moleculesP E LipskyRheumatology (Oxford, England)|January 26, 2000
The impact of pharmaco-economic considerations on the utilization of novel anti-rheumatic therapiesP E Lipsky, A KavanaughThe Journal of Rheumatology|June 1, 1993
Immunosuppression by the disease modifying antirheumatic drug bucillamine: inhibition of human T lymphocyte function by bucillamine and its metabolitesK Hashimoto, P E LipskyThe Medical Clinics of North America|January 1, 1997
Treatment of rheumatoid arthritisR Jain, P E LipskyThe Journal of Clinical Investigation|March 1, 1977
Inhibition of antigen- and mitogen-induced human lymphocyte proliferation by gold compoundsP E Lipsky, M ZiffArthritis and Rheumatism|June 1, 1994
Comparative inhibitory effects of bucillamine and D-penicillamine on the function of human B cells and T cellsS Hirohata, P E LipskyPageof 38